References
- Tannock IF, Amir E, Booth CM, et al. Relevance of randomised controlled trials in oncology. Lancet Oncol. 2016;17(12):e560–e567.
- Sim I, Chan AW, Gulmezoglu AM, et al. Clinical trial registration: transparency is the watchword. Lancet. 2006;367(9523):1631–1633.
- Zarin DA, Tse T. Trust but verify: trial registration and determining fidelity to the protocol. Ann Intern Med. 2013;159(1):65–67.
- Liang F, Guo X, Zhang S, et al. Comparison of primary endpoints between publications, registries, and protocols of phase III cancer clinical trials. Oncotarget. 2017;8(57):97648–97656.
- Chan AW, Pello A, Kitchen J, et al. Association of trial registration with reporting of primary outcomes in protocols and publications. JAMA. 2017;318(17):1709–1711.
- The New England Journal of Medicine. Editorial Policies. [cited 2020 May 7]. Available from: https://www.nejm.org/author-center/new-manuscripts.
- The Lancet. Information for Authors. [cited 2020 May 7]. Available from:https://www.thelancet.com/pb/assets/raw/Lancet/authors/lancet-information-for-authors.pdf.
- Consort. Transparent Reporting of Trials. [cited 2020 May 7]. Available from:http://www.consort-statement.org/checklists/view/32–consort-2010/66-title.
- De Angelis C, International Committee of Medical Journal Editors, Drazen JM, Frizelle FA, et al. Clinical trial registration: a statement from the International Committee of Medical Journal Editors. N Engl J Med. 2004;351(12):1250–1251.
- Zarin DA, Tse T, Williams RJ, et al. Update on trial registration 11 years after the ICMJE policy was established. N Engl J Med. 2017;376(4):383–391.
- Department of Health and Human Services. Final rule – clinical trials registration and results information submission. Fed Regist. 2016;81:64981–65157.
- Wayant C, Scheckel C, Hicks C, et al. Evidence of selective reporting bias in hematology journals: A systematic review. PLoS One. 2017;12(6):e0178379.
- Sivendran S, Latif A, McBride RB, et al. Adverse event reporting in cancer clinical trial publications. J Clin Oncol. 2014;32(2):83–89.
- Shepshelovich D, Goldvaser H, Wang L, et al. Comparison of reporting phase I trial results in ClinicalTrials.gov and matched publications. Invest New Drugs. 2017;35(6):827–833.
- Zhang S, Liang F, Li W, et al. Comparison of eligibility criteria between protocols, registries, and publications of Cancer Clinical Trials. J Natl Cancer Inst. 2016;108(11).
- Raghav KP, Mahajan S, Yao JC, et al. From protocols to publications: a study in selective reporting of outcomes in randomized trials in oncology. JCO. 2015;33(31):3583–3590.
- Shepshelovich D, Tibau A, Molto C, et al. Assessment of frequency and reporting of changes in cancer trial design after initiation of patient accrual. JAMA Oncol. 2019;5(1):107–109.
- Suresh K, Chandrashekara S. Sample size estimation and power analysis for clinical research studies. J Hum Reprod Sci. 2012;5(1):7–13.
- Booth CM, Le Maître A, Ding K, et al. Presentation of nonfinal results of randomized controlled trials at major oncology meetings. J Clin Oncol. 2009;27(24):3938–3944.
- Elimova E, Seruga B, Jiang H, et al. Comparison of results between the first and updated reports of phase III clinical trials (RCTs). (abstr). JCO. 2014;32(15_suppl):6520–6520.
- Montori VM, Devereaux PJ, Adhikari NK, et al. Randomized trials stopped early for benefit: a systematic review. JAMA. 2005;294(17):2203–2209.
- Woloshin S, Schwartz LM, Bagley PJ, et al. Characteristics of interim publications of randomized clinical trials and comparison with final publications. JAMA. 2018;319(4):404–406.
- Ramagopalan S, Skingsley AP, Handunnetthi L, et al. Prevalence of primary outcome changes in clinical trials registered on ClinicalTrials.gov: a cross-sectional study [v1; ref status: indexed, http://f1000r.es/34l]. F1000Res. 2014;3:77.
- Huić M, Marušić M, Marušić A. Completeness and changes in registered data and reporting bias of randomized controlled trials in ICMJE journals after trial registration policy. PLoS One. 2011;6(9):e25258.
- Pranić S, Marušić A. Changes to registration elements and results in a cohort of Clinicaltrials.gov trials were not reflected in published articles. J Clin Epidemiol. 2016;70:26–37.
- Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369(6):507–516.
- Dimopoulos MA, Oriol A, Nahi H, et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375(14):1319–1331.
- FDA. Regulatory information. Establishment and Operation of Clinical Trial Data Monitoring Committees for Clinical Trial Sponsors. [cited 2019 Nov 12]. Available from: https://www.fda.gov/RegulatoryInformation/Guidances/ucm127069.htm#2.
- Smith MA, Ungerleider RS, Korn EL, et al. Role of independent data-monitoring committees in randomized clinical trials sponsored by the National Cancer Institute. J Clin Oncol. 1997;15(7):2736–2743.
- National Institute of Health. National Cancer Institute. Data Safety and Monitoring Guidelines. [cited 2019 Nov 12]. Available from: https://deainfo.nci.nih.gov/grantspolicies/datasafety.pdf.
- DeMets DL. Data monitoring committees: history and their future. Trials. 2013; 14(Suppl 1):I3.
- Chow SC, Corey R, Lin M. On the independence of data monitoring committee in adaptive design clinical trials. J Biopharm Stat. 2012;22(4):853–867.
- Fleming TR, Hennekens CH, Pfeffer MA, et al. Enhancing trial integrity by protecting the independence of data monitoring committees in clinical trials. J Biopharm Stat. 2014;24(5):968–975.
- Chan AW, Hróbjartsson A, Haahr MT, et al. Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. JAMA. 2004;291(20):2457–2465.
- Dal-Ré R, Marušić A. Prevention of selective outcome reporting: let us start from the beginning. Eur J Clin Pharmacol. 2016;72(10):1283–1288.
- Landman GW. Escitalopram for the prevention of pegnterferon-α2a associated depression. Ann Intern Med. 2013;158(2):139–140.
- Prasad V. Treatment of moderate to severe hidiadenitis suppurativa. Ann Intern Med. 2013;159(1):72.
- Obi Y, Hamano T. The change history of the INDEPENDENT Study in the ClinicalTrials.gov database. Am J Kidney Dis. 2014;63(1):164.
- Shepshelovich D, Yelin D, Gafter-Gvili A, et al. Comparison of reporting phase III randomized controlled trials of antibiotic treatment for common bacterial infections in ClinicalTrials.gov and matched publications. Clin Microbiol Infect. 2018;24(11):1211.e9–1211.
- Askie L. Trial registration records, updates, and protocols. Lancet. 2016;388(10042):341–342.
- Del Paggio JC, Tannock IF. The fragility of phase 3 trials supporting FDA-approved anticancer medicines: a retrospective analysis. Lancet Oncol. 2019;20(8):1065–1069.